A major breakthrough in wound care has been achieved in Changzhou’s Wujin district. Jiangsu Ruipei Life Sciences Co., Ltd. (Repatec), based in the West Taihu Lake Science and Technology Industrial Park, has officially received regulatory approval for its PrimCell® Autologous Cell Collector, making it the first domestically approved product of its kind in China. The device is classified under infusion, nursing, and protective medical instruments and is now cleared for clinical application.

This advancement builds on decades of progress in tissue-engineered skin technologies, which have revolutionized wound care by moving beyond conventional skin grafting. While tissue-engineered skin has provided promising solutions for wound healing, the complexity and high costs associated with in-vitro skin tissue cultivation have hindered its widespread clinical use.

PrimCell®, independently developed by Repatec, is an innovative skin repair system designed to treat burns, vitiligo, superficial scars, and chronic wounds. The technology enables rapid extraction of autologous skin cells from a patient’s healthy tissue for immediate reapplication to wounds—eliminating the need for external cultivation and significantly improving treatment efficiency. This innovation addresses a longstanding gap in China’s wound care and regenerative medicine landscape.

In addition to the PrimCell® collector, the company has developed a real-time cellular analysis system—a fully automated, high-throughput device capable of providing immediate data on cell concentration, viability, size, and clustering within the operating room. This system ensures that harvested skin cells consistently maintain over 90% viability, offering robust technical support for the therapeutic performance of the PrimCell® system.

扫一扫在手机打开当前页